CNBC's Kate Kelly reports the latest on the Herbalife stock saga between Carl Icahn and Bill Ackman.
Matthew Handley alleged Herbalife made "purposefully deceptive statements" in its Aug. 3 quarterly earnings conference call and regulatory filings.
Sources tell CNBC Carl Icahn may have been interested in unloading his Herbalife stock earlier in August, but for the right price.
Herbalife shares slumped after Bill Ackman said he was approached to take a stake in the firm.
Carl Icahn bought 2.3 million shares of Herbalife and criticized Bill Ackman for obsessing over his short position in the company.
Carl Icahn slammed Pershing Square's Bill Ackman for making false statements about Icahn's Herbalife investment.
CNBC's Susan Li reports that Carl Icahn has bought 2.3 million shares in Herbalife and released a statement in response to Pershing Square's Bill Ackman.
CNBC's Kate Kelly and CNBC Contributors Ron Insana and Herb Greenberg discuss the ongoing saga between Pershing Square's Bill Ackman and Carl Icahn over Herbalife.
Bill Ackman tells CNBC the past 12 months were the "worst period of performance" of his career, and the implosion of Valeant Pharmaceuticals was mostly to blame.
Bill Ackman tells CNBC he was approached indirectly by Carl Icahn to purchase a stake in Herbalife — his longtime short target.
CNBC's Scott Wapner reaches out to Herbalife's largest individual shareholder Bill Stiritz about his take on Herbalife, amid Pershing Square Capital Bill Ackman's negative comments on the company.
Bill Ackman, Pershing Square Capital, discusses his fund's performance and the general hedge fund environment.
It's interesting the board now knows that Carl Ichan in a seller, says Bill Ackman, Pershing Square Capital, adding that the company is under enormous scrutiny and must change its business.
I would spend $30 million to get Carl out, says Bill Ackman, Pershing Square Capital talking about being contacted to buy a block share of Herbalife. Carl Ichan is the last man standing, says Ackman.
Sources told the WSJ that investment bank Jefferies Group had been looking for buyers for Icahn's stake worth roughly $1 billion.
CNBC's Meg Tirrell reports the latest details on Valeant and its potential criminal probe. The "Fast Money Halftime Report" traders and Yana Barton, Eaton Vance portfolio manager, add perspective.
Some of the names on the move ahead of the open.
The news comes just days after Ackman announced the firm was selling its shares in Canadian Pacific Railway.
Valeant Pharmaceuticals fortunes were discussed at a private shareholder dinner attended by top investor and board member William Ackman.
Valeant Pharmaceuticals reported quarterly earnings and revenue that fell short of analysts' expectations on Tuesday.